IL311476A - CCR2-directed antibodies - Google Patents

CCR2-directed antibodies

Info

Publication number
IL311476A
IL311476A IL311476A IL31147624A IL311476A IL 311476 A IL311476 A IL 311476A IL 311476 A IL311476 A IL 311476A IL 31147624 A IL31147624 A IL 31147624A IL 311476 A IL311476 A IL 311476A
Authority
IL
Israel
Prior art keywords
antibody
seq
ccr2
human
antibody fragment
Prior art date
Application number
IL311476A
Other languages
English (en)
Hebrew (he)
Inventor
Mack Matthias
Original Assignee
Granite Bio Ag
Mack Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Granite Bio Ag, Mack Matthias filed Critical Granite Bio Ag
Publication of IL311476A publication Critical patent/IL311476A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL311476A 2021-10-27 2022-10-25 CCR2-directed antibodies IL311476A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21204904 2021-10-27
PCT/EP2022/079744 WO2023072916A1 (en) 2021-10-27 2022-10-25 Antibodies targeting ccr2

Publications (1)

Publication Number Publication Date
IL311476A true IL311476A (en) 2024-05-01

Family

ID=78413745

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311476A IL311476A (en) 2021-10-27 2022-10-25 CCR2-directed antibodies

Country Status (10)

Country Link
US (2) US12168692B1 (https=)
EP (1) EP4423131A1 (https=)
JP (1) JP2024540196A (https=)
KR (1) KR20240099211A9 (https=)
CN (1) CN118159562A (https=)
AU (1) AU2022378899A1 (https=)
CA (1) CA3231124A1 (https=)
IL (1) IL311476A (https=)
MX (1) MX2024004447A (https=)
WO (1) WO2023072916A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245988A1 (en) * 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ｃｃｒ２に対する抗体
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
WO2016079276A1 (en) 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease

Also Published As

Publication number Publication date
US20240392018A1 (en) 2024-11-28
AU2022378899A1 (en) 2024-03-07
MX2024004447A (es) 2024-05-08
KR20240099211A (ko) 2024-06-28
US12168692B1 (en) 2024-12-17
CN118159562A (zh) 2024-06-07
JP2024540196A (ja) 2024-10-31
WO2023072916A1 (en) 2023-05-04
KR20240099211A9 (ko) 2025-12-10
EP4423131A1 (en) 2024-09-04
CA3231124A1 (en) 2023-05-04
US20250059288A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
CN116041516A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
WO2022105914A1 (zh) Cd70抗体及其应用
JP2024531462A (ja) Ｆａｐ／ｃｄ４０結合分子及びその医薬的使用
US20250059288A1 (en) Antibodies targeting ccr2
US20250382362A1 (en) Antibodies targeting il3
AU2023304700A1 (en) Antibodies targeting cd117
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
WO2024245988A1 (en) Antibodies targeting ccr2
HK40111251A (zh) 靶向ccr2的抗体
US12304958B2 (en) Antibodies targeting ActRIIA and ActRIIB
WO2024213046A1 (en) Anti-cd25 antibody and uses thereof
WO2022262828A1 (zh) 抗il-36r抗体及其用途
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
WO2024133890A1 (en) Antibodies targeting cd45
EA045935B1 (ru) Антитела к cd3 и их применение